KEAP1 and neoplasm: Sorafenib could kill the tumor by inducing ROS accumulation and promoting the overload of lipid peroxide [6].However, the high ROS level induced by sorafenib may result in abnormal activation of the p62–Keap1–Nrf2 pathway [10].